LBP-EC01

AXP000215.1 · Phage therapy

Platform
CRISPR-Cas3-enhanced phage cocktail (crPhage)
Originator
Locus Biosciences
Sponsor
Locus Biosciences

Names

NameTypeSource
LBP-EC01preferred name, codecurator, ctgov

Virus

Role
Phage
Family
Caudoviricetes
Virus
Escherichia coli bacteriophage (six-phage cocktail)
Replication
replicating
Modifications
each phage carries a CRISPR-Cas3 cassette targeting the E. coli genome
Transgenes
CRISPR-Cas3
Route
intraurethral, intravenous
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05488340A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)RecruitingPhase 22022-07-132027-06318Urinary Tract Infections
NCT04191148Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. ColiCompletedPhase 12019-12-302020-11-1936Urinary Tract Infections

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39134085Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.The Lancet. Infectious diseases2024cited by trial NCT05488340
PMID 33310655Enhancing phage therapy through synthetic biology and genome engineering.Current opinion in biotechnology2021cited by trial NCT04191148

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42199538CRISPR-Cas systems as next-generation antimicrobials: a systemic review of mechanisms, delivery strategies, and translational challenges.Frontiers in microbiology2026name in abstract: LBP-EC01
PMID 42262436CRISPR-based gene editing for antimicrobial resistance control in human medicine.Archives of microbiology2026name in abstract: LBP-EC01
PMID 43010175Engineered bacteriophages as precision antimicrobials against multidrug-resistant ESKAPE pathogens: molecular engineering strategies, clinical translation, and the crystallizing global regulatory landscape.Future science OA2026name in abstract: LBP-EC01
PMID 40733529Armed Phages: A New Weapon in the Battle Against Antimicrobial Resistance.Viruses2025name in abstract: LBP-EC01

Notes

Cocktail of six Escherichia coli phages, each carrying a CRISPR-Cas3 cassette that cuts the E. coli genome. Phase 1b NCT04191148 dosed it by intraurethral instillation; the phase 2 ELIMINATE trial NCT05488340 gives intraurethral plus intravenous doses. Target bacterium is not an HGNC symbol, so targets is empty.

How to cite

LBP-EC01 (AXP000215.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000215.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.